The Interferon Type I Signature Towards Prediction of Non-Response to Rituximab in Rheumatoid Arthritis Patients

Annals of the Rheumatic Diseases - United Kingdom
doi 10.1136/annrheumdis-2011-201230.11
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

Importance of Correlation Between Gene Expression Levels: Application to the Type I Interferon Signature in Rheumatoid Arthritis

PLoS ONE
Multidisciplinary
2011English

Type I Interferon Response Gene Expression in Established Rheumatoid Arthritis Is Not Associated With Clinical Parameters

Arthritis Research & Therapy
2016English

Variants of Genes Implicated in Type 1 Interferon Pathway and B-Cell Activation Modulate the EULAR Response to Rituximab at 24 Weeks in Rheumatoid Arthritis

RMD Open
RheumatologyAllergyImmunology
2017English

Rituximab Therapy in Greek Patients With Rheumatoid Arthritis

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2008English

Safety of Rituximab in Rheumatoid Arthritis

Reumatismo
Rheumatology
2011English

Non-Response to Rituximab Therapy in Rheumatoid Arthritis Is Associated With Incomplete Disruption of the B Cell Receptor Repertoire

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
2019English

Longterm Safety of Patients Receiving Rituximab in Rheumatoid Arthritis Clinical Trials

Journal of Rheumatology
RheumatologyAllergyImmunology
2010English

FRI0224 Rituximab Selectively Reduces Igg4 Levels in Rheumatoid Arthritis Patients

2017English

NK Cell Count as Predictor of Clinical Response in Patients With Rheumatoid Arthritis Treated With Rituximab

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy